RemeGen

Forecast & Rating7 analysts currently cover RemeGen, with about 71.4% giving a positive rating — meaning they expect the stock to rise. The average price target is ¥146.22, about 24.6% upside from the current price of ¥117.34. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 68.9% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study RemeGen closely still see room for the stock to rise. Data as of Sep 15, 2026; for reference only and not investment advice.